Alpha 2.0

» Articles » PMID: 38214869

Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials

Overview

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2024 Jan 12

PMID 38214869

Authors

Authors

Daniel A Gomes

Joao Presume

Pedro de Araujo Goncalves

Manuel Sousa Almeida

Miguel Mendes

Jorge Ferreira

Affiliations

Affiliations

Soon will be listed here.

Abstract

Purpose: Reduction of major atherosclerotic cardiovascular events (MACE) has not been consistent among different glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to assess the association between the magnitude of glycemic control, body weight loss, and reductions in systolic blood pressure (SBP) and low-density lipoprotein cholesterol (LDL-C) achieved through GLP-1 RA therapy and MACE.

Methods: Electronic databases (MEDLINE, CENTRAL, SCOPUS) were searched through March 2023. Studies were eligible if they were cardiovascular outcome trials (CVOTs) comparing GLP-1 RAs versus placebo in T2DM patients. The outcome of interest was 3-point MACE - cardiovascular death, myocardial infarction, or stroke. Random-effects meta-regression analyses evaluated the associations between reductions of HbA, body weight, SBP and LDL-C and reduction of MACE.

Results: Overall, 8 CVOTs were included (60079 patients, 30693 with GLP-1 RAs). Reductions of HbA were associated with the reduction of 3P-MACE (Log RR -0.290 [95% CI -0.515;-0.064], p = 0.012), with an estimated RR reduction of 25% for each 1% absolute reduction in HbA levels. Body weight loss was associated with the reduction of 3P-MACE (Log RR -0.068 [95% CI -0.135;-0.001], p = 0.047), with an estimated RR reduction of 7% for each 1 kg reduction in body weight. Reductions of SBP (Log RR -0.058 [95% CI -0.192;0.076], p = 0.396) and LDL-C (Log RR -0.602 [95% CI -4.157;2.953], p = 0.740) were not associated with the reduction of 3P-MACE.

Conclusions: In T2DM patients, more potent GLP-1 RAs in reducing HbA1c and body weight were associated with greater reductions of MACE.

Citing Articles

New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review.

Jalil J, Gabrielli L, Ocaranza M, MacNab P, Fernandez R, Grassi B Int J Mol Sci. 2024; 25(8).

PMID: 38673991 PMC: 11049921. DOI: 10.3390/ijms25084407.

How to assess kidney outcomes in obese people with substantial weight loss: the case of GLP1- and dual-receptor agonists.

Rothberg A, Herman W Nephrol Dial Transplant. 2024; 39(7):1060-1062.

PMID: 38299776 PMC: 11210982. DOI: 10.1093/ndt/gfae024.

References

1.

Sarwar N, Gao P, Kondapally Seshasai S, Gobin R, Kaptoge S, Di Angelantonio E . Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215-22. PMC: 2904878. DOI: 10.1016/S0140-6736(10)60484-9. View

2.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2008; 360(2):129-39. DOI: 10.1056/NEJMoa0808431. View

3.

Calles-Escandon J, Lovato L, Simons-Morton D, Kendall D, Pop-Busui R, Cohen R . Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010; 33(4):721-7. PMC: 2845012. DOI: 10.2337/dc09-1471. View

4.

Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M . Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22. PMC: 4985288. DOI: 10.1056/NEJMoa1603827. View

5.

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

6.

Hernandez A, Green J, Janmohamed S, DAgostino Sr R, Granger C, Jones N . Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018; 392(10157):1519-1529. DOI: 10.1016/S0140-6736(18)32261-X. View

7.

Gerstein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193):121-130. DOI: 10.1016/S0140-6736(19)31149-3. View

8.

Gerstein H, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes R . Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021; 385(10):896-907. DOI: 10.1056/NEJMoa2108269. View

9.

Lee Y, Jun H . Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2013; 63(1):9-19. DOI: 10.1016/j.metabol.2013.09.010. View

10.

Sattar N, Lee M, Kristensen S, Branch K, Del Prato S, Khurmi N . Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021; 9(10):653-662. DOI: 10.1016/S2213-8587(21)00203-5. View

11.

Heuvelman V, van Raalte D, Smits M . Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res. 2019; 116(5):916-930. DOI: 10.1093/cvr/cvz323. View

12.

Sposito A, Berwanger O, de Carvalho L, Kerr Saraiva J . GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol. 2018; 17(1):157. PMC: 6292070. DOI: 10.1186/s12933-018-0800-2. View

13.

Usman M, Siddiqi T, Anker S, Bakris G, Bhatt D, Filippatos G . Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. J Am Coll Cardiol. 2023; 81(25):2377-2387. DOI: 10.1016/j.jacc.2023.04.034. View

14.

Guh D, Zhang W, Bansback N, Amarsi Z, Birmingham C, Anis A . The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9:88. PMC: 2667420. DOI: 10.1186/1471-2458-9-88. View

15.

Oikonomou E, Antoniades C . The role of adipose tissue in cardiovascular health and disease. Nat Rev Cardiol. 2018; 16(2):83-99. DOI: 10.1038/s41569-018-0097-6. View

16.

van Veldhuisen S, Gorter T, van Woerden G, de Boer R, Rienstra M, Hazebroek E . Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2022; 43(20):1955-1969. PMC: 9123239. DOI: 10.1093/eurheartj/ehac071. View

17.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

18.

Pfeffer M, Claggett B, Diaz R, Dickstein K, Gerstein H, Kober L . Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015; 373(23):2247-57. DOI: 10.1056/NEJMoa1509225. View

19.

Holman R, Bethel M, Mentz R, Thompson V, Lokhnygina Y, Buse J . Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(13):1228-1239. PMC: 9792409. DOI: 10.1056/NEJMoa1612917. View

20.

Husain M, Birkenfeld A, Donsmark M, Dungan K, Eliaschewitz F, Franco D . Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019; 381(9):841-851. DOI: 10.1056/NEJMoa1901118. View